\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\:\ \(4\)\
\-\ pth\\ \\=\\ 85\\.1\\ \\ \\(normal\\ range\\:\\ \\ 13\\-65\\)\ \(0\)\
\-\ ca\\+\\+\\ \\=\\ 10\\.9\\ \\ \\(normal\\ range\\:\\ \\ 8\\.4\\-10\\.2\\)\ \(0\)\
\-\ vit\\ d\\ \\=\\ normal\ \(0\)\
\-\ surgical\\ excision\\,\\ follow\\-up\\ labs\\ to\\ ensure\\ normalization\ \(0\)\
\-\ early\\ images\\:\\ \\ small\\ \\ focus\\ of\\ increased\\ radiotracer\\ accumulation\\ at\\ the\\ left\\ lower\\ thyroid\\ region\\,\\ which\\ appears\\ extraglandular\ \(0\)\
\-\ late\\ images\\:\\ \\ appropriate\\ thyroid\\ washout\\ with\\ the\\ focus\\ of\\ increased\\ radiotracer\\ accumulation\\ at\\ the\\ left\\ lower\\ thyroid\\ region\\,\\ now\\ more\\ evident\ \(0\)\
\-\ parathyroid\\ adenoma\\:\\ \\ probable\\ \\-\\ pending\\ surgical\\ confirmation\ \(0\)\
\-\ 1\\)\\ \\ parathyroid\\ adenoma\ \(0\)\
\-\ 2\\)\\ \\ less\\ likely\\ an\\ exophytic\\ thyroid\\ adenoma\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ 3\\)\\ \\ thyroidal\\ or\\ extrathyroidal\\ malignancy\\,\\ lymphoma\\,\\ etc\ \(0\)\
\-\ 56\\ y\\/o\\ male\\ with\\ recurrent\\ kidney\\ stones\\ and\\ elevated\\ pth\\.\ \(0\)\
\-\ early\\ images\\ \\ \\(\\‚\\Ä\\úthyroid\\ phase\\‚\\Ä\\ù\\)\\ \ \(0\)\
\-\ prominent\\ thyroid\\ uptake\\,\\ also\\ salivary\\ glands\\ \ \(1\)\
\-\ often\\ can\\ see\\ focal\\ uptake\\ in\\ parathyroid\\ adenoma\ \(1\)\
\-\ delayed\\ images\\ \\ \\(\\‚\\Ä\\úparathyroid\\ phase\\‚\\Ä\\ù\\)\\ \\ \ \(0\)\
\-\ most\\ of\\ thyroid\\ uptake\\ has\\ washed\\ out\\ \ \(1\)\
\-\ a\\ focal\\ area\\ of\\ residual\\ activity\\ \\(adenoma\\)\\ or\\ multiple\\ foci\\ of\\ activity\\ \\(hyperplasia\\ or\\ multiple\\ adenomas\\)\\ will\\ be\\ seen\ \(1\)\
\-\ sensitivity\\ for\\ 300\\ mg\\ adenomas\\ is\\ approx\\ 85\\-90\\%\ \(0\)\
\-\ false\\ negative\\:\\ \\ small\\ size\\ and\\ lower\\ sensitivity\\ for\\ hyperplasia\\ \\(50\\-60\\%\\)\\.\ \(0\)\
\-\ false\\ positive\\:\\ \\ most\\ common\\ is\\ a\\ thyroid\\ adenoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.13342142647332234\ \(0\)\
\-\ parathyroid\\:\\ 0\\.10312992461532082\ \(0\)\
\-\ adenoma\\:\\ 0\\.10195698148017178\ \(0\)\
\-\ \\-false\\:\\ 0\\.08395731832349047\ \(0\)\
\-\ \\=\\:\\ 0\\.0640683583382881\ \(0\)\
\-\ pth\\:\\ 0\\.0554265347658334\ \(0\)\
\-\ adenomas\\:\\ 0\\.05409546864797475\ \(0\)\
\-\ uptake\\:\\ 0\\.048499763209917314\ \(0\)\
\-\ sensitivity\\:\\ 0\\.045966994070497376\ \(0\)\
\-\ accumulation\\:\\ 0\\.043360367113573176\ \(0\)\
\-\ \\:\\:\\ 0\\.043058088228215816\ \(0\)\
\-\ 85\\.1\\:\\ 0\\.04197865916174524\ \(0\)\
\-\ 13\\-65\\:\\ 0\\.04197865916174524\ \(0\)\
\-\ extraglandular\\:\\ 0\\.04197865916174524\ \(0\)\
\-\ \\-late\\:\\ 0\\.04197865916174524\ \(0\)\
\-\ \\-prominent\\:\\ 0\\.04197865916174524\ \(0\)\
\-\ \\-most\\:\\ 0\\.04197865916174524\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.0400985546474134\ \(0\)\
\-\ \\-early\\:\\ 0\\.03867795830193597\ \(0\)\
\-\ thyroidal\\:\\ 0\\.03867795830193597\ \(0\)\
\-\ extrathyroidal\\:\\ 0\\.03867795830193597\ \(0\)\
\-\ \\-often\\:\\ 0\\.03867795830193597\ \(0\)\
\-\ \\-a\\:\\ 0\\.03867795830193597\ \(0\)\
\-\ phase\\:\\ 0\\.03828312265114055\ \(0\)\
\-\ radiotracer\\:\\ 0\\.03797337796823046\ \(0\)\
\-\ washed\\:\\ 0\\.03674717207284947\ \(0\)\
\-\ focus\\:\\ 0\\.03655985410996118\ \(0\)\
\-\ 85\\-90\\:\\ 0\\.035377257442126706\ \(0\)\
\-\ 8\\.4\\-10\\.2\\:\\ 0\\.03431466910253523\ \(0\)\
\-\ \\)\\:\\ 0\\.03397798533872881\ \(0\)\
\-\ 10\\.9\\:\\ 0\\.03344647121304021\ \(0\)\
\-\ 50\\-60\\:\\ 0\\.03344647121304021\ \(0\)\
\-\ range\\:\\ 0\\.03276419063126032\ \(0\)\
\-\ ca\\+\\+\\:\\ 0\\.03271242035671993\ \(0\)\
\-\ vit\\:\\ 0\\.03271242035671993\ \(0\)\
\-\ normalization\\:\\ 0\\.03271242035671993\ \(0\)\
\-\ images\\:\\ 0\\.03122407413236865\ \(0\)\
\-\ activity\\:\\ 0\\.030533777416967035\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.030395246835992002\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.03022487002884176\ \(0\)\
\-\ 300\\:\\ 0\\.029411719496910668\ \(0\)\
\-\ labs\\:\\ 0\\.028304514351763222\ \(0\)\
\-\ washout\\:\\ 0\\.02821498412414445\ \(0\)\
\-\ salivary\\:\\ 0\\.027480933267824168\ \(0\)\
\-\ lower\\:\\ 0\\.02745517241948375\ \(0\)\
\-\ approx\\:\\ 0\\.026463913742595314\ \(0\)\
\-\ exophytic\\:\\ 0\\.024783811958677494\ \(0\)\
\-\ confirmation\\:\\ 0\\.02441256652310744\ \(0\)\
\-\ glands\\:\\ 0\\.024180232408014906\ \(0\)\
\-\ \\(\\:\\ 0\\.024078724208128684\ \(0\)\
\-\ ensure\\:\\ 0\\.023644622963125906\ \(0\)\
\-\ probable\\:\\ 0\\.023446181551694627\ \(0\)\
\-\ focal\\:\\ 0\\.023242796229889544\ \(0\)\
\-\ region\\:\\ 0\\.02298667835466012\ \(0\)\
\-\ mg\\:\\ 0\\.02232563828057813\ \(0\)\
\-\ etc\\:\\ 0\\.022027922294952727\ \(0\)\
\-\ 56\\:\\ 0\\.02141919195442947\ \(0\)\
\-\ stones\\:\\ 0\\.02093656102938048\ \(0\)\
\-\ d\\:\\ 0\\.020293531106504562\ \(0\)\
\-\ residual\\:\\ 0\\.02019432116887198\ \(0\)\
\-\ increased\\:\\ 0\\.019909378874282437\ \(0\)\
\-\ appropriate\\:\\ 0\\.01918107943421168\ \(0\)\
\-\ normal\\:\\ 0\\.019137320779987158\ \(0\)\
\-\ \\%\\:\\ 0\\.01898400984139055\ \(0\)\
\-\ small\\:\\ 0\\.01874833604172494\ \(0\)\
\-\ evident\\:\\ 0\\.018620207835847946\ \(0\)\
\-\ pending\\:\\ 0\\.01760726005499878\ \(0\)\
\-\ foci\\:\\ 0\\.01746678070072879\ \(0\)\
\-\ recurrent\\:\\ 0\\.017171582243452752\ \(0\)\
\-\ multiple\\:\\ 0\\.01714100955694542\ \(0\)\
\-\ surgical\\:\\ 0\\.017106874002394797\ \(0\)\
\-\ excision\\:\\ 0\\.01670119393602521\ \(0\)\
\-\ delayed\\:\\ 0\\.016561811163167524\ \(0\)\
\-\ malignancy\\:\\ 0\\.0157242365609596\ \(0\)\
\-\ appears\\:\\ 0\\.015146327718082138\ \(0\)\
\-\ early\\:\\ 0\\.014881709379249704\ \(0\)\
\-\ kidney\\:\\ 0\\.014335159309761952\ \(0\)\
\-\ or\\:\\ 0\\.014307467842338679\ \(0\)\
\-\ now\\:\\ 0\\.013910074236674513\ \(0\)\
\-\ elevated\\:\\ 0\\.01380626838742411\ \(0\)\
\-\ less\\:\\ 0\\.01378066668725087\ \(0\)\
\-\ size\\:\\ 0\\.013642266054184627\ \(0\)\
\-\ out\\:\\ 0\\.013447875604088173\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.01323827138781782\ \(0\)\
\-\ positive\\:\\ 0\\.013204217096591033\ \(0\)\
\-\ area\\:\\ 0\\.012865886876829845\ \(0\)\
\-\ will\\:\\ 0\\.01273086199228163\ \(0\)\
\-\ negative\\:\\ 0\\.012152953149404164\ \(0\)\
\-\ see\\:\\ 0\\.01214389148204185\ \(0\)\
\-\ lymphoma\\:\\ 0\\.011629517306616599\ \(0\)\
\-\ likely\\:\\ 0\\.01147757126636027\ \(0\)\
\-\ y\\/o\\:\\ 0\\.011269662046760194\ \(0\)\
\-\ at\\:\\ 0\\.011026315741253649\ \(0\)\
\-\ common\\:\\ 0\\.010648891485506655\ \(0\)\
\-\ more\\:\\ 0\\.01017703004434365\ \(0\)\
\-\ 1\\:\\ 0\\.009682506514093843\ \(0\)\
\-\ 3\\:\\ 0\\.00952845488907876\ \(0\)\
\-\ most\\:\\ 0\\.009394453055847981\ \(0\)\
\-\ can\\:\\ 0\\.009229630249852714\ \(0\)\
\-\ left\\:\\ 0\\.009105764469265856\ \(0\)\
\-\ 2\\:\\ 0\\.008762402364335935\ \(0\)\
\-\ \\-\\:\\ 0\\.008722516470039828\ \(0\)\
\-\ seen\\:\\ 0\\.008041083881274716\ \(0\)\
\-\ also\\:\\ 0\\.008021998065095959\ \(0\)\
\-\ \\,\\:\\ 0\\.007734573300493925\ \(0\)\
\-\ has\\:\\ 0\\.007641428430925134\ \(0\)\
\-\ which\\:\\ 0\\.007595926605916899\ \(0\)\
\-\ male\\:\\ 0\\.007358121608987968\ \(0\)\
\-\ for\\:\\ 0\\.006943887129930621\ \(0\)\
\-\ be\\:\\ 0\\.0062750320159234724\ \(0\)\
\-\ an\\:\\ 0\\.0056269755442129995\ \(0\)\
\-\ is\\:\\ 0\\.005355150270330721\ \(0\)\
\-\ of\\:\\ 0\\.0027739000189997243\ \(0\)\
\-\ to\\:\\ 0\\.002033657659252316\ \(0\)\
\-\ in\\:\\ 0\\.002006653476858357\ \(0\)\
\-\ the\\:\\ 0\\.0019749897814803686\ \(0\)\
\-\ a\\:\\ 0\\.0018885704848504825\ \(0\)\
\-\ and\\:\\ 0\\.0017143714831639855\ \(0\)\
\-\ with\\:\\ 0\\.0011143254865703786\ \(0\)\
\-\ \\.\\:\\ 0\\.0005071362299620897\ \(0\)\
